ProteinQure to Unveil New Data on PQ203 at San Antonio Symposium

ProteinQure, a leader in computational peptide therapeutics, will present new findings on their triple negative breast cancer drug PQ203 at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a Peptide Drug Conjugate targeting the Sortilin receptor, a promising approach for treating this aggressive cancer subtype.

Recent data indicates PQ203's strong efficacy in patient-derived models, especially those resistant to current standards like Sacituzumab Govitecan. Additionally, the drug showcases a favorable safety profile. ProteinQure is conducting GLP-toxicology studies to support an investigational drug application, expected in Q2 2025.

The company plans to start Phase 1 trials in late 2025 at the Princess Margaret Cancer Center in Toronto and other North American hospitals. ProteinQure remains committed to advancing this innovative treatment to clinical trials.